Sunset Capital Assets（SNST）株式概要エイフェックス・バイオクレンズ・システムズ社は、アルコールを使用しない除菌液を開発している。 詳細SNST ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析財務データは報告されていない 意味のある時価総額がありません ( $266K )株式の流動性は非常に低い すべてのリスクチェックを見るSNST Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.001該当なし内在価値ディスカウントEst. Revenue$PastFuture012016201920222025202620282031Revenue US$1.0Earnings US$0.09AdvancedSet Fair ValueView all narrativesSunset Capital Assets, Inc. 競合他社Titanium Holdings GroupSymbol: OTCPK:TTHGMarket cap: US$1.2mShinecoSymbol: OTCPK:SISIMarket cap: US$249.7kMiami Breeze Car CareSymbol: OTCPK:MIBEMarket cap: US$80.1mNevis BrandsSymbol: OTCPK:NEVI.FMarket cap: US$840.8k価格と性能株価の高値、安値、推移の概要Sunset Capital Assets過去の株価現在の株価US$0.00152週高値US$0.00152週安値US$0.0001ベータ01ヶ月の変化150.00%3ヶ月変化n/a1年変化900.00%3年間の変化-86.67%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Feb 19Aphex BioCleanse Systems, Inc Suspends Director Scott SmithAphex BioCleanse Systems, Inc. announces it has come to the attention of the Board of Directors of Aphex BioCleanse Systems, Inc., that on February 10, 2022, Board Member Scott Smith filed a legal action in the U.S. District Court for Massachusetts against the Company and two of its Directors. The object of the lawsuit is not to benefit the Company's shareholders but to financially benefit Scott Smith individually, and the litigation potentially damages shareholder interests. This litigation also clearly violates the "Schoon Doctrine", (Schoon v. Smith, No. 554, 2006 Del. Feb. 12, 2008) Accordingly, the Chairman of the Aphex Board of Directors, Thomas Fitzgerald has determined, effective immediately, to suspend Scott Smith from any, and all duties as a Board Director, pending a complete investigation of this matter and allow a review by the other full Board members.お知らせ • Jun 12Sunset Capital Assets, Inc. (OTCPK:SNST) acquired Business of US BioSolutions LLC.Sunset Capital Assets, Inc. (OTCPK:SNST) acquired Business of US BioSolutions LLC on June 11, 2021. As a part of the transaction, Sunset Capital Assets also acquired a patented Open-Cell Foam technology. The acquired business includes the product line: BioFoam face shields (BioShield), Wipes (BioWipes), Mitts (BioMitt), and Sponges (BioSponge), and a Hand Sanitizer and Surface Cleaner (BioWash). Scott Smith, Inventor of BioFoam will join Sunset Capital Assets as Chief Sustainability Officer. Sunset Capital Assets, Inc. (OTCPK:SNST) completed the acquisition of Business of US BioSolutions LLC on June 11, 2021.お知らせ • Mar 04Aphex Biocleanse Systems Announces Significant Purchase Order for Proprietary Non-Toxic Disinfecting Wipe AlternativeAphex BioCleanse Systems, Inc. announced that the Company has received a significant initial purchase order ("PO") from eTECH Channel, which has been helping companies build successful sales channels since 2014, for its proprietary Hy-IQ® Water non-toxic disinfecting wipes. eTECH Channel intends to offer Aphex's disinfecting wipes, which were announced last week, to its extensive distribution channel under the name Hy-IQ® Hand Wipes (the "Wipes"). This initial PO is for 4,950 gallons of 10x concentration DermAphex® product and fills requests for several of eTECH Channel's major national retail clients. Hy-IQ® Hand Wipes conform to the FDA monograph for hand disinfecting products that will be available in retail and healthcare facilities through eTECH Channel shortly.お知らせ • Feb 24Aphex BioCleanse Systems Broadens Offerings to Include Non-Toxic Sanitizing WipesAphex BioCleanse Systems, Inc. announced that the company has broadened its product offerings to include non-toxic sanitizing wipes formulated with its proprietary Hy-IQ® Water technology. Third-party studies have proven Hy-IQ® Water is effective against human coronavirus, swine flu, E. coli, influenza, Candida auris, Candida albicans, MRSA, and several additional pathogens. Hy-IQ® Water achieves these results through physics rather than chemicals, so Aphex sanitizing products are both highly effective and non-toxic. The global disinfectant products market is expected to reach $30.11 billion by 2027 partly due to an increase in demand for sanitizers and disinfectants during the COVID-19 pandemic. This presents a large market opportunity for Aphex's sanitizing wipes, which are the only water-based and non-toxic option on the market. The company will soon be announcing partnerships with several large-scale distributors that would like to offer its sanitizing wipes to their channels and is open to additional opportunities.お知らせ • Dec 18Aphex Biocleanse Systems Signs European Supply and Private Label Agreement for Dermaphex and Sanaphex ProductsAphex BioCleanse Systems, Inc. announced that the company has signed a supply and private label agreement with Qurexx B.V. ("Qurexx"). As part of the agreement, and following required European registration processes, Qurexx holds the authority to purchase, market and sell Aphex's DermAphex Hand Sanitizer and SanAphex Hard Surface Sanitizer throughout the European Union, the United Kingdom, Switzerland and Eastern Europe. Qurexx will purchase the products directly from Aphex and is expected to place a significant purchase order in the near future following the required European product registration approvals. Through this agreement, Aphex will leverage Qurexx's key partnerships and distribution channels to increase accessibility of the Company's water-based sanitization products across Europe. As part of its European expansion, Aphex has also registered its DermAphex® Hand Sanitizer and SanAphex® Hard Surface Sanitizer in Germany. With this registration, the Company can now begin shipping and selling products in the country.お知らせ • Nov 13Aphex BioCleanse Systems Appoints Mark Washo as Senior Vice President of Sales and MarketingAphex BioCleanse Systems, Inc. announced that seasoned sports and business marketing executive Mark Washo has joined the Company as Senior Vice President of Sales and Marketing. Prior to joining Aphex, Washo held a number of respected senior marketing positions over the course of almost three decades. In his most recent role, he served as the Chief Business Officer of Marina Auto Stadium and the Rochester Rhinos where he managed the day to day operations of the stadium and professional USL soccer team.最新情報をもっと見るRecent updatesお知らせ • Feb 19Aphex BioCleanse Systems, Inc Suspends Director Scott SmithAphex BioCleanse Systems, Inc. announces it has come to the attention of the Board of Directors of Aphex BioCleanse Systems, Inc., that on February 10, 2022, Board Member Scott Smith filed a legal action in the U.S. District Court for Massachusetts against the Company and two of its Directors. The object of the lawsuit is not to benefit the Company's shareholders but to financially benefit Scott Smith individually, and the litigation potentially damages shareholder interests. This litigation also clearly violates the "Schoon Doctrine", (Schoon v. Smith, No. 554, 2006 Del. Feb. 12, 2008) Accordingly, the Chairman of the Aphex Board of Directors, Thomas Fitzgerald has determined, effective immediately, to suspend Scott Smith from any, and all duties as a Board Director, pending a complete investigation of this matter and allow a review by the other full Board members.お知らせ • Jun 12Sunset Capital Assets, Inc. (OTCPK:SNST) acquired Business of US BioSolutions LLC.Sunset Capital Assets, Inc. (OTCPK:SNST) acquired Business of US BioSolutions LLC on June 11, 2021. As a part of the transaction, Sunset Capital Assets also acquired a patented Open-Cell Foam technology. The acquired business includes the product line: BioFoam face shields (BioShield), Wipes (BioWipes), Mitts (BioMitt), and Sponges (BioSponge), and a Hand Sanitizer and Surface Cleaner (BioWash). Scott Smith, Inventor of BioFoam will join Sunset Capital Assets as Chief Sustainability Officer. Sunset Capital Assets, Inc. (OTCPK:SNST) completed the acquisition of Business of US BioSolutions LLC on June 11, 2021.お知らせ • Mar 04Aphex Biocleanse Systems Announces Significant Purchase Order for Proprietary Non-Toxic Disinfecting Wipe AlternativeAphex BioCleanse Systems, Inc. announced that the Company has received a significant initial purchase order ("PO") from eTECH Channel, which has been helping companies build successful sales channels since 2014, for its proprietary Hy-IQ® Water non-toxic disinfecting wipes. eTECH Channel intends to offer Aphex's disinfecting wipes, which were announced last week, to its extensive distribution channel under the name Hy-IQ® Hand Wipes (the "Wipes"). This initial PO is for 4,950 gallons of 10x concentration DermAphex® product and fills requests for several of eTECH Channel's major national retail clients. Hy-IQ® Hand Wipes conform to the FDA monograph for hand disinfecting products that will be available in retail and healthcare facilities through eTECH Channel shortly.お知らせ • Feb 24Aphex BioCleanse Systems Broadens Offerings to Include Non-Toxic Sanitizing WipesAphex BioCleanse Systems, Inc. announced that the company has broadened its product offerings to include non-toxic sanitizing wipes formulated with its proprietary Hy-IQ® Water technology. Third-party studies have proven Hy-IQ® Water is effective against human coronavirus, swine flu, E. coli, influenza, Candida auris, Candida albicans, MRSA, and several additional pathogens. Hy-IQ® Water achieves these results through physics rather than chemicals, so Aphex sanitizing products are both highly effective and non-toxic. The global disinfectant products market is expected to reach $30.11 billion by 2027 partly due to an increase in demand for sanitizers and disinfectants during the COVID-19 pandemic. This presents a large market opportunity for Aphex's sanitizing wipes, which are the only water-based and non-toxic option on the market. The company will soon be announcing partnerships with several large-scale distributors that would like to offer its sanitizing wipes to their channels and is open to additional opportunities.お知らせ • Dec 18Aphex Biocleanse Systems Signs European Supply and Private Label Agreement for Dermaphex and Sanaphex ProductsAphex BioCleanse Systems, Inc. announced that the company has signed a supply and private label agreement with Qurexx B.V. ("Qurexx"). As part of the agreement, and following required European registration processes, Qurexx holds the authority to purchase, market and sell Aphex's DermAphex Hand Sanitizer and SanAphex Hard Surface Sanitizer throughout the European Union, the United Kingdom, Switzerland and Eastern Europe. Qurexx will purchase the products directly from Aphex and is expected to place a significant purchase order in the near future following the required European product registration approvals. Through this agreement, Aphex will leverage Qurexx's key partnerships and distribution channels to increase accessibility of the Company's water-based sanitization products across Europe. As part of its European expansion, Aphex has also registered its DermAphex® Hand Sanitizer and SanAphex® Hard Surface Sanitizer in Germany. With this registration, the Company can now begin shipping and selling products in the country.お知らせ • Nov 13Aphex BioCleanse Systems Appoints Mark Washo as Senior Vice President of Sales and MarketingAphex BioCleanse Systems, Inc. announced that seasoned sports and business marketing executive Mark Washo has joined the Company as Senior Vice President of Sales and Marketing. Prior to joining Aphex, Washo held a number of respected senior marketing positions over the course of almost three decades. In his most recent role, he served as the Chief Business Officer of Marina Auto Stadium and the Rochester Rhinos where he managed the day to day operations of the stadium and professional USL soccer team.お知らせ • Oct 13Aphex BioCleanse Systems, Inc. Announces Management AppointmentsAphex BioCleanse Systems, Inc. announced that Kevin Harrington and Mark Timm have joined the Company as advisors. Harrington joins Aphex at a key moment in the Company's growth as sanitization products are in high demand due to the global COVID-19 pandemic. The hand sanitizer market alone, which includes Aphex's alcohol-free hand sanitizer DermAphex®, is expected to see a compound annual growth rate (CAGR) of almost 46% in 2020. Throughout his career, Harrington has worked behind the scenes of business ventures and produced more than $5 billion in global sales. He has assisted in the successful launch of more than 500 products, in making dozens of millionaires and has been responsible for the launch of more than 20 businesses that have each topped $100 million in revenue. He has also been involved with iconic brands and celebrities such as Jack Lalanne, Tony Little, George Foreman. and Kim Kardashian, among others.株主還元SNSTUS Household ProductsUS 市場7D0%2.2%1.0%1Y900.0%-13.5%28.7%株主還元を見る業界別リターン: SNST過去 1 年間で-13.5 % の収益を上げたUS Household Products業界を上回りました。リターン対市場: SNST過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。価格変動Is SNST's price volatile compared to industry and market?SNST volatilitySNST Average Weekly Movementn/aHousehold Products Industry Average Movement3.4%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: SNSTの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のSNSTのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2010n/an/awww.aphexus.comエイフェックス・バイオクレンズ・システムズ社は、アルコールを使用しない除菌ソリューションを開発している。同社の製品には、除菌剤、表面消毒剤、創傷洗浄剤、家畜処理用溶液などがある。同社は2010年に法人化され、ニューヨーク州ロチェスターに拠点を置く。もっと見るSunset Capital Assets, Inc. 基礎のまとめSunset Capital Assets の収益と売上を時価総額と比較するとどうか。SNST 基礎統計学時価総額US$265.92k収益（TTM）US$0売上高(TTM)n/an/aPER（株価収益率n/aP/SレシオSNST は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SNST 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$0収益US$0直近の収益報告該当なし次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%SNST の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 16:49終値2026/05/19 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sunset Capital Assets, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 19Aphex BioCleanse Systems, Inc Suspends Director Scott SmithAphex BioCleanse Systems, Inc. announces it has come to the attention of the Board of Directors of Aphex BioCleanse Systems, Inc., that on February 10, 2022, Board Member Scott Smith filed a legal action in the U.S. District Court for Massachusetts against the Company and two of its Directors. The object of the lawsuit is not to benefit the Company's shareholders but to financially benefit Scott Smith individually, and the litigation potentially damages shareholder interests. This litigation also clearly violates the "Schoon Doctrine", (Schoon v. Smith, No. 554, 2006 Del. Feb. 12, 2008) Accordingly, the Chairman of the Aphex Board of Directors, Thomas Fitzgerald has determined, effective immediately, to suspend Scott Smith from any, and all duties as a Board Director, pending a complete investigation of this matter and allow a review by the other full Board members.
お知らせ • Jun 12Sunset Capital Assets, Inc. (OTCPK:SNST) acquired Business of US BioSolutions LLC.Sunset Capital Assets, Inc. (OTCPK:SNST) acquired Business of US BioSolutions LLC on June 11, 2021. As a part of the transaction, Sunset Capital Assets also acquired a patented Open-Cell Foam technology. The acquired business includes the product line: BioFoam face shields (BioShield), Wipes (BioWipes), Mitts (BioMitt), and Sponges (BioSponge), and a Hand Sanitizer and Surface Cleaner (BioWash). Scott Smith, Inventor of BioFoam will join Sunset Capital Assets as Chief Sustainability Officer. Sunset Capital Assets, Inc. (OTCPK:SNST) completed the acquisition of Business of US BioSolutions LLC on June 11, 2021.
お知らせ • Mar 04Aphex Biocleanse Systems Announces Significant Purchase Order for Proprietary Non-Toxic Disinfecting Wipe AlternativeAphex BioCleanse Systems, Inc. announced that the Company has received a significant initial purchase order ("PO") from eTECH Channel, which has been helping companies build successful sales channels since 2014, for its proprietary Hy-IQ® Water non-toxic disinfecting wipes. eTECH Channel intends to offer Aphex's disinfecting wipes, which were announced last week, to its extensive distribution channel under the name Hy-IQ® Hand Wipes (the "Wipes"). This initial PO is for 4,950 gallons of 10x concentration DermAphex® product and fills requests for several of eTECH Channel's major national retail clients. Hy-IQ® Hand Wipes conform to the FDA monograph for hand disinfecting products that will be available in retail and healthcare facilities through eTECH Channel shortly.
お知らせ • Feb 24Aphex BioCleanse Systems Broadens Offerings to Include Non-Toxic Sanitizing WipesAphex BioCleanse Systems, Inc. announced that the company has broadened its product offerings to include non-toxic sanitizing wipes formulated with its proprietary Hy-IQ® Water technology. Third-party studies have proven Hy-IQ® Water is effective against human coronavirus, swine flu, E. coli, influenza, Candida auris, Candida albicans, MRSA, and several additional pathogens. Hy-IQ® Water achieves these results through physics rather than chemicals, so Aphex sanitizing products are both highly effective and non-toxic. The global disinfectant products market is expected to reach $30.11 billion by 2027 partly due to an increase in demand for sanitizers and disinfectants during the COVID-19 pandemic. This presents a large market opportunity for Aphex's sanitizing wipes, which are the only water-based and non-toxic option on the market. The company will soon be announcing partnerships with several large-scale distributors that would like to offer its sanitizing wipes to their channels and is open to additional opportunities.
お知らせ • Dec 18Aphex Biocleanse Systems Signs European Supply and Private Label Agreement for Dermaphex and Sanaphex ProductsAphex BioCleanse Systems, Inc. announced that the company has signed a supply and private label agreement with Qurexx B.V. ("Qurexx"). As part of the agreement, and following required European registration processes, Qurexx holds the authority to purchase, market and sell Aphex's DermAphex Hand Sanitizer and SanAphex Hard Surface Sanitizer throughout the European Union, the United Kingdom, Switzerland and Eastern Europe. Qurexx will purchase the products directly from Aphex and is expected to place a significant purchase order in the near future following the required European product registration approvals. Through this agreement, Aphex will leverage Qurexx's key partnerships and distribution channels to increase accessibility of the Company's water-based sanitization products across Europe. As part of its European expansion, Aphex has also registered its DermAphex® Hand Sanitizer and SanAphex® Hard Surface Sanitizer in Germany. With this registration, the Company can now begin shipping and selling products in the country.
お知らせ • Nov 13Aphex BioCleanse Systems Appoints Mark Washo as Senior Vice President of Sales and MarketingAphex BioCleanse Systems, Inc. announced that seasoned sports and business marketing executive Mark Washo has joined the Company as Senior Vice President of Sales and Marketing. Prior to joining Aphex, Washo held a number of respected senior marketing positions over the course of almost three decades. In his most recent role, he served as the Chief Business Officer of Marina Auto Stadium and the Rochester Rhinos where he managed the day to day operations of the stadium and professional USL soccer team.
お知らせ • Feb 19Aphex BioCleanse Systems, Inc Suspends Director Scott SmithAphex BioCleanse Systems, Inc. announces it has come to the attention of the Board of Directors of Aphex BioCleanse Systems, Inc., that on February 10, 2022, Board Member Scott Smith filed a legal action in the U.S. District Court for Massachusetts against the Company and two of its Directors. The object of the lawsuit is not to benefit the Company's shareholders but to financially benefit Scott Smith individually, and the litigation potentially damages shareholder interests. This litigation also clearly violates the "Schoon Doctrine", (Schoon v. Smith, No. 554, 2006 Del. Feb. 12, 2008) Accordingly, the Chairman of the Aphex Board of Directors, Thomas Fitzgerald has determined, effective immediately, to suspend Scott Smith from any, and all duties as a Board Director, pending a complete investigation of this matter and allow a review by the other full Board members.
お知らせ • Jun 12Sunset Capital Assets, Inc. (OTCPK:SNST) acquired Business of US BioSolutions LLC.Sunset Capital Assets, Inc. (OTCPK:SNST) acquired Business of US BioSolutions LLC on June 11, 2021. As a part of the transaction, Sunset Capital Assets also acquired a patented Open-Cell Foam technology. The acquired business includes the product line: BioFoam face shields (BioShield), Wipes (BioWipes), Mitts (BioMitt), and Sponges (BioSponge), and a Hand Sanitizer and Surface Cleaner (BioWash). Scott Smith, Inventor of BioFoam will join Sunset Capital Assets as Chief Sustainability Officer. Sunset Capital Assets, Inc. (OTCPK:SNST) completed the acquisition of Business of US BioSolutions LLC on June 11, 2021.
お知らせ • Mar 04Aphex Biocleanse Systems Announces Significant Purchase Order for Proprietary Non-Toxic Disinfecting Wipe AlternativeAphex BioCleanse Systems, Inc. announced that the Company has received a significant initial purchase order ("PO") from eTECH Channel, which has been helping companies build successful sales channels since 2014, for its proprietary Hy-IQ® Water non-toxic disinfecting wipes. eTECH Channel intends to offer Aphex's disinfecting wipes, which were announced last week, to its extensive distribution channel under the name Hy-IQ® Hand Wipes (the "Wipes"). This initial PO is for 4,950 gallons of 10x concentration DermAphex® product and fills requests for several of eTECH Channel's major national retail clients. Hy-IQ® Hand Wipes conform to the FDA monograph for hand disinfecting products that will be available in retail and healthcare facilities through eTECH Channel shortly.
お知らせ • Feb 24Aphex BioCleanse Systems Broadens Offerings to Include Non-Toxic Sanitizing WipesAphex BioCleanse Systems, Inc. announced that the company has broadened its product offerings to include non-toxic sanitizing wipes formulated with its proprietary Hy-IQ® Water technology. Third-party studies have proven Hy-IQ® Water is effective against human coronavirus, swine flu, E. coli, influenza, Candida auris, Candida albicans, MRSA, and several additional pathogens. Hy-IQ® Water achieves these results through physics rather than chemicals, so Aphex sanitizing products are both highly effective and non-toxic. The global disinfectant products market is expected to reach $30.11 billion by 2027 partly due to an increase in demand for sanitizers and disinfectants during the COVID-19 pandemic. This presents a large market opportunity for Aphex's sanitizing wipes, which are the only water-based and non-toxic option on the market. The company will soon be announcing partnerships with several large-scale distributors that would like to offer its sanitizing wipes to their channels and is open to additional opportunities.
お知らせ • Dec 18Aphex Biocleanse Systems Signs European Supply and Private Label Agreement for Dermaphex and Sanaphex ProductsAphex BioCleanse Systems, Inc. announced that the company has signed a supply and private label agreement with Qurexx B.V. ("Qurexx"). As part of the agreement, and following required European registration processes, Qurexx holds the authority to purchase, market and sell Aphex's DermAphex Hand Sanitizer and SanAphex Hard Surface Sanitizer throughout the European Union, the United Kingdom, Switzerland and Eastern Europe. Qurexx will purchase the products directly from Aphex and is expected to place a significant purchase order in the near future following the required European product registration approvals. Through this agreement, Aphex will leverage Qurexx's key partnerships and distribution channels to increase accessibility of the Company's water-based sanitization products across Europe. As part of its European expansion, Aphex has also registered its DermAphex® Hand Sanitizer and SanAphex® Hard Surface Sanitizer in Germany. With this registration, the Company can now begin shipping and selling products in the country.
お知らせ • Nov 13Aphex BioCleanse Systems Appoints Mark Washo as Senior Vice President of Sales and MarketingAphex BioCleanse Systems, Inc. announced that seasoned sports and business marketing executive Mark Washo has joined the Company as Senior Vice President of Sales and Marketing. Prior to joining Aphex, Washo held a number of respected senior marketing positions over the course of almost three decades. In his most recent role, he served as the Chief Business Officer of Marina Auto Stadium and the Rochester Rhinos where he managed the day to day operations of the stadium and professional USL soccer team.
お知らせ • Oct 13Aphex BioCleanse Systems, Inc. Announces Management AppointmentsAphex BioCleanse Systems, Inc. announced that Kevin Harrington and Mark Timm have joined the Company as advisors. Harrington joins Aphex at a key moment in the Company's growth as sanitization products are in high demand due to the global COVID-19 pandemic. The hand sanitizer market alone, which includes Aphex's alcohol-free hand sanitizer DermAphex®, is expected to see a compound annual growth rate (CAGR) of almost 46% in 2020. Throughout his career, Harrington has worked behind the scenes of business ventures and produced more than $5 billion in global sales. He has assisted in the successful launch of more than 500 products, in making dozens of millionaires and has been responsible for the launch of more than 20 businesses that have each topped $100 million in revenue. He has also been involved with iconic brands and celebrities such as Jack Lalanne, Tony Little, George Foreman. and Kim Kardashian, among others.
